Education
About Us
Working with TipRanks
Follow Us
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
Earnings Data
Report Date
Sep 25, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
0.31Last Year’s EPS
-0.82Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 17.78%
|Next Earnings Date:Sep 25, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth, positive net income, and successful strategic initiatives. Although there was a decline in gross margin due to higher cost inventory, the overall sentiment remains positive due to the company's operational efficiency and the success of the Aytu RxConnect platform.Company Guidance
In the Aytu BioPharma fiscal 2025 Q3 earnings call, the company reported a 32% increase in total revenue, driven by a 25% growth in the ADHD portfolio and a 77% growth in the pediatric portfolio. The implementation of cost reduction initiatives led to a $1.6 million decrease in operating expenses, resulting in a $2.4 million income from operations. This quarter marked the second time the company achieved positive income from operations and the third consecutive quarter of positive net income, totaling $4 million. Earnings per share were $0.65, contrasting with a $0.52 loss per share in the previous year. Adjusted EBITDA reached $3.9 million, up from $0.9 million in the prior year. The company highlighted its strategic focus on leveraging the Aytu RxConnect platform and its CNS-focused sales team to drive future growth through potential in-licensed or acquired products.Significant Revenue Growth
Total revenue grew by 32% year-over-year, led by a 25% increase in the ADHD portfolio and a 77% increase in the pediatric portfolio.
Positive Income from Operations
Achieved income from operations of $2.4 million, marking the second quarter of positive income from operations in the company's history.
Net Income Improvement
Net income was $4 million, compared to a $2.9 million loss in the same quarter last year, translating to basic earnings per share of $0.65.
Adjusted EBITDA Growth
Adjusted EBITDA increased to $3.9 million from $0.9 million a year ago.
Operational Efficiency
Operating expenses decreased by $1.6 million, reflecting effective cost reduction initiatives.
Successful Strategic Initiatives
The company halted clinical development, wound down its Consumer Health business, outsourced manufacturing, and refinanced its long-term note.
Aytu RxConnect Platform Success
Aytu RxConnect was credited with contributing to revenue growth and providing a network of about 1,000 pharmacies that support patient access.
AYTU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AYTU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.35 | $2.59 | +91.85% |
Feb 12, 2025 | $1.39 | $1.38 | -0.72% |
Nov 13, 2024 | $1.74 | $1.55 | -10.92% |
Sep 26, 2024 | $2.85 | $2.36 | -17.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aytu BioScience Inc (AYTU) report earnings?
Aytu BioScience Inc (AYTU) is schdueled to report earning on Sep 25, 2025, TBA Not Confirmed.
What is Aytu BioScience Inc (AYTU) earnings time?
Aytu BioScience Inc (AYTU) earnings time is at Sep 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AYTU EPS forecast?
AYTU EPS forecast for the fiscal quarter 2025 (Q4) is 0.31.